Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H13ClFN3O |
Molecular Weight | 341.767 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC1=NC=C2CN=C(C3=C(F)C=CC=C3)C4=C(C=CC(Cl)=C4)N12
InChI
InChIKey=QHSMEGADRFZVNE-UHFFFAOYSA-N
InChI=1S/C18H13ClFN3O/c19-11-5-6-16-14(7-11)18(13-3-1-2-4-15(13)20)22-9-12-8-21-17(10-24)23(12)16/h1-8,24H,9-10H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28615640Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17998299 | https://www.ncbi.nlm.nih.gov/pubmed/10606840 | https://www.ncbi.nlm.nih.gov/pubmed/16220317
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28615640
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17998299 | https://www.ncbi.nlm.nih.gov/pubmed/10606840 | https://www.ncbi.nlm.nih.gov/pubmed/16220317
1-Hydroxymidazolam (Alpha-hydroxy-midazolam) is pharmacologically active midazolam metabolite, which is, like the parent drug midazolam a neuronal depressant drug. There are numerous studies in which the statements concerning the contribution of 1-Hydroxymidazolam to the clinical actions of midazolam range from “almost equipotent” to “no major contributing factor”. In humans, Hydroxymidazolam is subject to further glucuronidation, followed by renal excretion. In humans, urinary recovery of 1-Hydroxymidazolam glucuronide accounted for 60 to 70% of an administered dose of [14C]midazolam. 1-Hydroxymidazolam and it’s glucuronide were found in patients with renal failure after administration of midazolam and may account for the prolonged sedation observed in those patients.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL6196 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10606840 |
|||
Target ID: CHEMBL4370 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10606840 |
|||
Target ID: CHEMBL1907607 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28615640 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10606840
short i. v. injection of 0.15 mg/kg-1 alpha-hydroxy-midazolam
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17998299
The reaction mixture consisted of 1’-hydroxymidazolam (5–200 _M), 100 mM potassium phosphate buffer (pH 7.5) with 2 mM MgCl2, and human/rat liver microsomes (0.5 mg of protein/ml) or recombinant UGTs (1 mg of protein/ml) treated with alamethicin at 50 mkg/mg of microsomal protein. The reactions were initiated by the addition of UDPGA (2 mM), incubated at 37°C, and terminated with ice-cold acetonitrile containing 0.2% formic acid and phenolphthalein-beta-D-glucuronide as the internal standard. Samples were centrifuged at 3220g for 15 min, and supernatants were subjected to LC-MS/MS analysis.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
E5142BN92Z
Created by
admin on Sat Dec 16 08:17:00 GMT 2023 , Edited by admin on Sat Dec 16 08:17:00 GMT 2023
|
PRIMARY | |||
|
100000176065
Created by
admin on Sat Dec 16 08:17:00 GMT 2023 , Edited by admin on Sat Dec 16 08:17:00 GMT 2023
|
PRIMARY | |||
|
59468-90-5
Created by
admin on Sat Dec 16 08:17:00 GMT 2023 , Edited by admin on Sat Dec 16 08:17:00 GMT 2023
|
PRIMARY | |||
|
107917
Created by
admin on Sat Dec 16 08:17:00 GMT 2023 , Edited by admin on Sat Dec 16 08:17:00 GMT 2023
|
PRIMARY | |||
|
DTXSID50208175
Created by
admin on Sat Dec 16 08:17:00 GMT 2023 , Edited by admin on Sat Dec 16 08:17:00 GMT 2023
|
PRIMARY |
PARENT (METABOLITE ACTIVE)
SUBSTANCE RECORD